mitoxantrone has been researched along with HIV Infections in 3 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
HIV Infections: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The pharmacokinetic comparability of Prolastin-C to Prolastin was assessed in subjects with AAT deficiency." | 2.75 | Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. ( Brantly, ML; Campos, MA; Chapman, KR; Kueppers, F; Sandhaus, RA; Stocks, JM; Strange, C; Turino, G; Wang-Smith, L, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hogg, ME | 1 |
| Popowich, DA | 1 |
| Wang, EC | 1 |
| Kiel, KD | 1 |
| Stryker, SJ | 1 |
| Halverson, AL | 1 |
| Stocks, JM | 1 |
| Brantly, ML | 1 |
| Wang-Smith, L | 1 |
| Campos, MA | 1 |
| Chapman, KR | 1 |
| Kueppers, F | 1 |
| Sandhaus, RA | 1 |
| Strange, C | 1 |
| Turino, G | 1 |
| Tirelli, U | 1 |
| Errante, D | 1 |
| Spina, M | 1 |
| Gastaldi, R | 1 |
| Nigra, E | 1 |
| Nosari, AM | 1 |
| Magnani, G | 1 |
| Vaccher, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-center, Randomized, Double-blind, Crossover Trial to Evaluate the Pharmacokinetic Comparability of Alpha-1 MP to Prolastin in Subjects With Alpha1-antitrypsin Deficiency.[NCT00295061] | Phase 3 | 24 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary objective of this study was to demonstrate the pharmacokinetic comparability (geometric least square mean ratio of AUC between the Alpha-1 MP vs. Prolastin®, 90% confidence interval falls within 0.80-1.25, FDA Guidance as being bioequivalent between two treatments) of Alpha-1 MP to Prolastin® in subjects with alpha-1-anti-trypsin (AAT) deficiency by comparing AUC from Day 0 to Day 7 of plasma Alpha1-PI measured by the functional activity (potency) assay. AUC from Day 0 to Day 7 was calculated at steady state at the end of the first and second 8-week treatment periods during the 16-week double-blind, crossover phase." (NCT00295061)
Timeframe: Day 0 to Day 7
| Intervention | mg*h/mL (Number) |
|---|---|
| Alpha-1 MP | 155.9 |
| Prolastin | 152.4 |
2 trials available for mitoxantrone and HIV Infections
| Article | Year |
|---|---|
Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study.
Topics: alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Antineoplastic Combined Chemotherapy Protocols; | 2010 |
Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; HIV Infections; Humans; Ly | 1996 |
1 other study available for mitoxantrone and HIV Infections
| Article | Year |
|---|---|
HIV and anal cancer outcomes: a single institution's experience.
Topics: Antineoplastic Agents; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvan | 2009 |